The sharp rise in parents declining a newborn’s intramuscular vitamin K dose is measurably increasing infant bleeding, including dangerous intracranial hemorrhage; the evidence base is large, consistent, and squarely supports routine prophylaxis.
At a Glance
- Across a national cohort of 5.2 million infants, those who did not receive intramuscular vitamin K had higher six‑month bleeding rates than recipients.
- The relative increase in any documented bleeding was about 47%, with an especially strong association for intracranial hemorrhage.
- Refusal is rising: nonreceipt climbed from roughly 3% of newborns in 2017 to nearly 7% by 2025.
- Findings align with a second nationwide database analysis linking lower vitamin K use to more diagnoses of vitamin K deficiency and associated bleeding.
What the new evidence shows, and why it matters
Two large analyses anchor the current understanding. First, a retrospective cohort study using electronic health records from 5.2 million U.S. infants found higher bleeding incidence within six months among babies who did not receive intramuscular vitamin K at birth compared with those who did. Rates for any bleeding were 288 versus 186 per 10,000 births; for intracranial bleeding—a severe outcome—the gap was 33.0 versus 13.2 per 10,000, corresponding to an adjusted relative risk of 2.43 (95% CI, 2.26–2.62) for nonrecipients. A companion JAMA report framed the finding succinctly: approximately 2.9% of nonrecipients experienced a bleeding event versus 1.9% of recipients, a 47% relative increase.
Second, a JAMA Pediatrics analysis of more than 11 million infants tracked practice patterns and outcomes over time, reporting that vitamin K supplementation decreased as diagnoses of vitamin K deficiency and vitamin K–deficiency bleeding increased between 2017 and 2025. Taken together, the studies connect the trend (declining uptake) to the consequence (more deficiency and bleeding diagnoses) and quantify the clinical gradient between receipt and nonreceipt in a very large, contemporary U.S. population.
Mechanism: why newborns need vitamin K up front
The biology is straightforward. Vitamin K is required to gamma-carboxylate specific clotting factors (II, VII, IX, X) and proteins C and S; deficient infants cannot generate stable clots, predisposing them to spontaneous or procedure-related hemorrhage. Newborns begin life with low hepatic vitamin K stores, placental transfer is limited, breast milk contains relatively little vitamin K, and the neonatal gut microbiome—an endogenous source later in life—has not yet matured. A single intramuscular dose immediately after birth provides a depot that reliably raises and sustains levels through the highest-risk window, covering early and late vitamin K–deficiency bleeding. This pharmacologic logic underpins long-standing pediatric guidance and explains the disproportionate increase in serious bleeds—especially intracranial—when the injection is declined.
How we got here: from standard prophylaxis to rising refusals
Routine intramuscular vitamin K prophylaxis has been U.S. standard of care since the 1960s; the American Academy of Pediatrics endorsed a single dose in 1961, a position echoed in modern practice statements. For decades, acceptance was near-universal and VKDB—once a feared neonatal diagnosis—receded from view. Over the last several years, however, refusal has risen. In the 5.2‑million‑infant cohort, nonreceipt more than doubled from 3.1% in 2017 to 6.8% in 2025. Researchers and children’s hospitals describe the same arc in their institutional communications, warning that a once-rare declination has become a regular challenge in newborn units.
What the numbers actually mean: absolute risk, relative risk, and severity
Interpreting risk correctly matters for parents and clinicians. The headline 47% relative increase pertains to “any” coded bleeding event over six months, which aggregates minor and severe episodes; the absolute difference in that broad category is roughly 1 percentage point. The more consequential signal is in serious bleeding. Intracranial hemorrhage—low-frequency but high-impact—is more than twice as likely when vitamin K is declined, and those events drive the most devastating outcomes in survivors. This gradient mirrors earlier observational work that also found higher odds of both overall and intracranial bleeding without intramuscular prophylaxis, reinforcing consistency across datasets and eras.
Study design and what it does—and does not—claim
The JAMA cohort is observational, using de‑identified electronic records; it establishes robust associations but, by design, cannot prove that every individual bleed was caused by nonreceipt. The data come from organizations contributing to a large EHR network, which, while expansive, may not capture all U.S. births or every encounter uniformly. Those caveats do not erase the signal: multiple, very large samples show aligned direction and clinically credible magnitudes, and the strongest effect concentrates in intracranial bleeding—a pathophysiologically coherent endpoint for vitamin K deficiency. A reasonable reading is that declining uptake is contributing to preventable serious hemorrhage at the population level, even as absolute risks for any individual infant remain modest.
Comparators and alternatives: why intramuscular dosing remains the reference standard
Some parents ask about oral vitamin K. While various oral regimens exist internationally, they require multiple doses and meticulous adherence and have shown higher failure rates for late VKDB compared with a single intramuscular dose—particularly in exclusively breastfed infants. The U.S. evidence base and practice tradition therefore favor intramuscular administration as the most reliable protection across early and late windows. Clinically, reliability is the point: in a setting where missed or delayed doses can translate into intracranial bleeding weeks after birth, a one‑time depot injection has a decisive adherence advantage. The current U.S. data linking nonreceipt to higher bleeding rates arrive against that backdrop and reinforce why the injection remains the benchmark.
An 11-day-old baby reportedly suffered hours of uncontrolled bleeding while waiting for a critical Vitamin K shot in the ER. A heartbreaking case raising serious questions about newborn care and emergency response. 💔
Read more: https://t.co/qwSL8efIvj#NewbornHealth #VitaminK pic.twitter.com/FLyBwsT8up
— Olivia Ross (@OliviaRoss70) November 10, 2026
Implications for practice and communication
Three practical steps follow from the evidence. First, normalize prenatal counseling: discussions about vitamin K land better before delivery, when parents are gathering information rather than making decisions in the exhaustion of the postpartum hour. Second, present both absolute and relative risk clearly; explain that although most newborns will not bleed, the injection shifts the odds decisively, especially against severe brain hemorrhage. Third, separate vitamin K from vaccine debates; this is a one‑time vitamin depot to prevent a known deficiency state, not an immunization. Health systems can also audit documentation to distinguish explicit refusal from missing data and, where appropriate, implement opt‑out workflows that still respect consent while minimizing inadvertent omissions.
Sources:
washingtontimes.com, jamanetwork.com, inquirer.com, clinicalfutures.research.chop.edu, detroitnews.com
